Studies on mast cells and histamine release in psoriasis: The effect of ranitidine

Acta Dermato-Venereologica

Volumn 78, Issue 3, 1998, Pages 190-193

  Petersen, Lars J ^a,d   Hansen, Ulla ^b   Kristensen, Johannes K ^b   Nielsen, Henrik ^c   Skov, Per S ^c   Nielsen, Hans J ^b  

^a Bispebjerg University Hospital

^b HVIDOVRE HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

^d NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; HISTAMINE; HLA DR ANTIGEN; RANITIDINE; SUBSTANCE P;

ARTICLE; BASOPHIL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; HISTAMINE RELEASE; HUMAN; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MAST CELL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSORIASIS; TREATMENT OUTCOME;

CASE-CONTROL STUDIES; CD4-CD8 RATIO; FEMALE; HISTAMINE; HISTAMINE H2 ANTAGONISTS; HISTAMINE RELEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAST CELLS; PSORIASIS; RANITIDINE; SEVERITY OF ILLNESS INDEX; SKIN; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0031947637     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/000155598441503     Document Type: Article

References (24)

1. Elder JT. Cytokine and genetic regulation of psoriasis. Adv Dermatol 1995; 10: 99-133.
2. Barker JN. The immunopathology of psoriasis. Baillieres Clin Rheumatol 1994; 8: 429-438.
3. Brody I. Mast cell degranulation in the evolution of acute eruptive guttate psoriasis vulgaris. J Invest Dermatol 1984; 82: 460-464.
4. Schubert C, Christophers E. Mast cells and macrophages in early relapsing psoriasis. Arch Dermatol Res 1985; 277: 352-358.
5. Naukkarinen A, Harvima I, Paukkonen K, Aalto ML, Horsmanheimo M. Immunohistochemical analysis of sensory nerves and neuropeptides, and their contacts with mast cells in developing and mature psoriatic lesions. Arch Dermatol Res 1993; 285: 341-346.
6. Foreman JC. Non-immunological stimuli of mast cells and basophil leukocytes. In: Foreman JC, ed. Immunopharmacology of mast cells and basophils, London: Academic Press, 1993: 57-69.
7. Naukkarinen A, Harvima IT, Aalto ML, Horsmanheimo M. Mast cell tryptase and chymase are potential regulators of neurogenic inflammation in psoriatic skin. Int J Dermatol 1994; 33: 361-366.
8. Witkamp L, Velthuis PJ, Verhaegh MEJM, et al. An open prospective clinical trial with systemic ranitidine in the treatment of psoriasis. J Am Acad Dermatol 1993; 28: 778-781.
9. Kristensen JK, Petersen LJ, Hansen U, Nielsen H, Stahl Skov P, Nielsen HJ. Systemic high-dose ranitidine in the treatment of psoriasis: an open prospective clinical trial. Br J Dermatol 1995; 133: 905-908.
10. Nielsen HJ, Hammer JH. Possible role of histamine in pathogenesis of autoimmune diseases: implications for immunotherapy with histamine-2 receptor antagonists. Med Hypotheses 1992; 39: 349-355.
11. Petersen LJ, Kristensen JK, Bülow J. Microdialysis of the interstitial water space in human skin in vivo: quantitative measurement of cutaneous glucose concentrations. J Invest Dermatol 1992; 99: 357-360.
12. Petersen LJ, Poulsen LK. Søzndergaard J, Skov PS. The use of cutaneous microdialysis to measure substance P-induced histamine release in intact human skin in vivo. J Allergy Clin Immunol 1994; 94: 773-783.
13. Petersen LJ, Church MK, Skov PS. Platelet-activating factor induces histamine release from human skin mast cells in vivo which is reduced by local nerve blockade. J Allergy Clin Immunol 1997; 99: 640-647.
14. Mosbech H, Skov PS. House dust mite-induced histamine release from washed blood cells. Evaluation of effect parameters. Allergy 1987; 42: 553-555.
15. Stahl Skov P, Norn S, Weeke B. A new method for detecting histamine release. Agents Actions 1984; 14: 414-416.
16. Toyry S, Fraki J, Tammi R. Mast cell density in psoriatic skin. The effect of PUVA and corticosteroid therapy. Arch Dermatol Res 1988; 280: 282-285.
17. Borroni G, Vignati G, Zaccone C, Gorani A, Brazzelli V, Rabbiosi G. Photofibrosis: a further histopathological change induced by PUVA therapy via the mast cell in guttate psoriasis. Preliminary report. Acta Derm Venereol Suppl Stockh 1994; 186: 159-161.
18. Casolaro V, Galeone D, Giacummo A, Sanduzzi A, Melillo G, Marone G. Human basophil/mast cell releasibility. V. Functional comparisons of cells obtained from peripheral blood, lung parenchyma, and bronchoalveolar lavage in asthmatics. Am Rev Respir Dis 1989; 139: 1375-1382.
19. Broide DH, Gleich GJ, Cuomo AJ, et al. Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway. J Allergy Clin Immunol 1991; 88: 637-648.
20. Bedard PM, Brunet C, Pelletier G, Hebert J. Increased compound 48/80 induced local histamine release from nonlesional skin of patients with chronic urticaria. J Allergy Clin Immunol 1986; 78: 1121-1125.
21. Jacques P, Lavoie A, Bedard PM, Brunet C, Hebert J. Chronic idiopathic urticaria: profiles of skin mast cell histamine release during active disease and remission. J Allergy Clin Immunol 1992; 89: 1139-1143.
22. Petersen LJ, Brasso K, Pryds M, Skov PS. Histamine release in intact human skin by monocyte chemoattractant factor-1, RANTES, macrophage inflammatory protein-1, stem cell factor, anti-IgE, and codeine as determined by an ex vivo skin microdialysis technique. J Allergy Clin Immunol 1996; 98: 790-796.
23. Okayama Y, Brzezinska-Blaszczyk E, Kuna P, Kaplan AP, Church MK. Effects of PBMC-derived histamine-releasing factors on histamine release from human skin and lung mast cells. Clin Exp Allergy 1995; 25: 890-895.
24. 1-receptor antagonists in allergic diseases. New York: Marcel Dekker, 1996: 273-298.